Novo Nordisk A/S (NVO)
64.46
-1.60 (-2.42%)
At close: Apr 15, 2025, 3:59 PM
64.52
0.09%
After-hours: Apr 15, 2025, 05:59 PM EDT
-2.42% (1D)
| Bid | 64.51 |
| Market Cap | 280.11B |
| Revenue (ttm) | 290.4B |
| Net Income (ttm) | 100.99B |
| EPS (ttm) | 3.32 |
| PE Ratio (ttm) | 19.42 |
| Forward PE | 3.06 |
| Analyst | Buy |
| Ask | 64.68 |
| Volume | 5,545,545 |
| Avg. Volume (20D) | 9,671,975.8 |
| Open | 65.64 |
| Previous Close | 66.06 |
| Day's Range | 63.87 - 65.95 |
| 52-Week Range | 59.32 - 148.15 |
| Beta | 0.25 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Apr 30, 1981
Employees 76,302
Stock Exchange NYSE
Ticker Symbol NVO
Website https://www.novonordisk.com
Analyst Forecast
According to 4 analyst ratings, the average rating for NVO stock is "Buy." The 12-month stock price forecast is $160, which is an increase of 148.22% from the latest price.
Stock ForecastsNext Earnings Release
Novo Nordisk A/S is scheduled to release its earnings on May 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 days ago
+2.05%
Novo Nordisk shares are trading higher after Pfize...
Unlock content with
Pro Subscription
1 month ago
-9.43%
Novo Nordisk shares are trading lower after the company reported Phase 3 results for CagriSema, showing 15.7% weight loss over 68 weeks.
